Vera Therapeutics VERA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $259.99M+80.2% | $215.26M+70.6% | $189.29M+66.6% | $173.13M+93.7% | $144.25M+89.0% | ||
| $123.42M+152% | $100.22M+144% | $80.89M+155% | $62.92M+126% | $49M+91.8% | ||
| $383.41M+98.4% | $315.47M+88.7% | $270.18M+86.0% | $236.05M+101% | $193.25M+89.7% | ||
| -$383.41M-98.4% | -$315.47M-88.7% | -$270.18M-86.0% | -$236.05M-101% | -$193.25M-89.7% | ||
| $7.56M+0.7% | $7.53M-1.2% | $7.5M+10.1% | $7.47M+28.5% | $7.51M+55.9% | ||
| $14.46M-18.7% | $15.86M+5.6% | $18.24M+67.2% | $17.77M+89.2% | $17.79M+135% | ||
| —— | -$299.61M-96.9% | -$262.75M-90.2% | -$225.88M-82.1% | -$189.01M-71.8% | ||
| -$368.95M-110% | -$299.62M-96.9% | -$251.94M-87.5% | -$218.28M-102% | -$175.46M-86.1% | ||
| -$5.54-84.7% | -$4.66-69.5% | -$3.99-52.9% | -$3.58-62.0% | -$3.00-46.3% | ||
| -$382.89M-98.3% | -$315.01M-88.6% | -$269.79M-85.8% | -$235.77M-101% | -$193.07M-90.5% | ||
| -$383.41M-98.4% | -$315.47M-88.7% | -$270.18M-86.0% | -$236.05M-101% | -$193.25M-89.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vera Therapeutics profitable?
- Vera Therapeutics is not currently profitable: it reported a net loss of $369.0M over the trailing twelve months.
- What is Vera Therapeutics's earnings per share?
- Vera Therapeutics's diluted EPS over the trailing twelve months is $-5.54.
- Where does Vera Therapeutics's income statement data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.